For research use only. Not for therapeutic Use.
Mofezolac（Cat No.:I008130）, also known as Disopain and N-22, is a selective inhibitor of cyclooxygenase-1 (COX-1). It is primarily used for the treatment of pain, including musculoskeletal pain and arthritis. By selectively inhibiting COX-1, Mofezolac helps reduce inflammation and relieve pain symptoms. Its mechanism of action involves suppressing the production of prostaglandins, which are responsible for pain and inflammation. Mofezolac is considered a valuable therapeutic option for managing various types of pain, particularly those associated with musculoskeletal conditions and arthritis.
| Catalog Number | I008130 |
| CAS Number | 78967-07-4 |
| Synonyms | Mofezolac; Disopain; N-22; N 22; N22;2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid |
| Molecular Formula | C19H17NO5 |
| Purity | ≥95% |
| Target | COX |
| Solubility | Soluble in DMSO |
| Storage | 2-8°C |
| IUPAC Name | 2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid |
| InChI | InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22) |
| InChIKey | DJEIHHYCDCTAAH-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)C2=C(ON=C2C3=CC=C(C=C3)OC)CC(=O)O |
| Reference | </br>1:Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Miao L, Shiraishi R, Fujise T, Kuroki T, Kakimoto T, Sakata Y, Takashima T, Iwakiri R, Fujimoto K, Shi R, Li X.Hepatogastroenterology. 2011 Jan-Feb;58(105):81-8. PMID: 21510291 </br>2:Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Niho N, Kitamura T, Takahashi M, Mutoh M, Sato H, Matsuura M, Sugimura T, Wakabayashi K.Cancer Sci. 2006 Oct;97(10):1011-4. PMID: 16984374 Free Article</br>3:Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K.Carcinogenesis. 2002 Sep;23(9):1463-6. PMID: 12189188 </br>4:Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T.Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. PMID: 9777656 </br>5:[Fifty two-week chronic oral toxicity study of mofezolac (N-22) in rats]. Satoh K, Furukawa H, Nasu Y, Sone H, Ichiki T, Kodama R, Kuwata M, Yamashita K.J Toxicol Sci. 1990 Jun;15 Suppl 2:77-109. Japanese. PMID: 2231796 Free Article</br>6:[Three-month subacute oral toxicity study of mofezolac (N-22) in dogs]. Shimpo K, Takeuchi M, Kiguchi M, Iwata M, Nasu Y, Yada H, Yamashita K.J Toxicol Sci. 1990 Jun;15 Suppl 2:43-76. Japanese. PMID: 2231795 Free Article</br>7:[Antigenicity test of mofezolac (N-22)]. Takemoto M, Matsuo K, Katoh S, Yoshida R.J Toxicol Sci. 1990 Jun;15 Suppl 2:261-8. Japanese. PMID: 2231794 Free Article</br>8:Micronucleus test of mofezolac (N-22). Ohuchida A, Furukawa A.J Toxicol Sci. 1990 Jun;15 Suppl 2:253-60. PMID: 2231793 Free Article</br>9:Mutagenicity tests of mofezolac (N-22). Ohuchida A, Furukawa A.J Toxicol Sci. 1990 Jun;15 Suppl 2:239-51. PMID: 2231792 Free Article</br>10:[Reproductive and developmental toxicity study of mofezolac (N-22) (4)–Study by oral administration of N-22 during the perinatal and lactation periods in rats]. Yamakita O, Koida M, Shinomiya M, Katayama S, Ikebuchi K, Yoshida R.J Toxicol Sci. 1990 Jun;15 Suppl 2:219-37. Japanese. PMID: 2231791 Free Article |
